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Background
Influenza virus is a highly contagious human and animal
pathogen causing infections of the respiratory track. Pre-
vention such as high standard hygiene and vaccination
still represent the best measures for protection. Beside
the traditional egg-based influenza vaccine production,
numerous cell culture-based processes are currently
being established. Due to its ability to induce strong and
protective immune responses, the highly abundant gly-
coprotein hemagglutinin (HA) represents the major
component in influenza vaccines. Since variations in N-
glycosylation of glycoproteins such as HA can alter
quality characteristics of antigens, the impact of cell
lines and process parameters for vaccine manufacturing
needs to be addressed. This study investigates the
impact of virus adaptation and different harvest time
points on HA N-glycosylation. Therefore, the HA of
influenza A virus Uruguay/716/2007 (H3N2,h i g h
growth reassortant), in the following referred to as IVA-
Uruguay, was purified and N-glycans analyzed by capil-
lary gel electrophoresis with laser-induced fluorescence
(CGE-LIF).
Materials and methods
Cell culture and virus production
IVA-Uruguay (H3N2, #07/360, NIBSC, South Mimms,
UK) was produced in either adherently growing MDCK
(No. 84121903) or Vero (No. 88020401) cells purchased
from ECACC (Salisbury, UK) . For cell growth GMEM
(Invitrogen, #22100-093, Darmstadt, Germany) was sup-
plemented with 5.5 g/L glucose (Roth, #X997.3, Karls-
ruhe, Germany), 2 g/L peptone (IDG, #MC33,
Lancashire, UK), 10 % FCS (Invitrogen, #10270-106) and
4 mg/mL NaHCO3 (Roth, #6885.3). Infections were per-
formed in the same medium without addition of FCS
but supplemented with trypsin (Invitrogen, #27250-018)
at a final concentration of 5 U/mL. Virus was quantified
by a hemagglutination assay according to Kalbfuss et al.
[1] and is expressed in HAU (log HA/100 µL).
HA N-glycosylation pattern analysis
Virus was harvested and processed for HA N-glycosyla-
tion pattern analysis according to Schwarzer et al. [2]
applying an optimized work-flow [3] and data evaluation
[4]. Finally, the samples were separated by CGE-LIF
using an ABI PRISM 3100-Avant genetic analyzer
(Applied Biosystems, Foster City, California, USA). For
data processing and evaluation the x-axis of capillary
electropherograms was normalized using an internal
standard, resulting in N-glycosylation patterns, in which
each peak corresponds to at least one distinct N-glycan
structure. This allowed a direct qualitative comparison
regarding N-glycan structure presence in different sam-
ples. For quantitative comparison, the relative peak
height (RPH: the ratio of peak height to the total height
of all peaks) was determined for each peak and sample.
Low abundant peaks were defined with RPH < 5 %.
Results
MDCK cell-derived virus seed, exhibiting 2.6 HAU at 24
hours post infection (hpi; data not shown), was used to
infect five consecutive passages of Vero cells. Adaptation
of the virus to Vero cells resulted in increased virus
yields within shorter time frames in the new host sys-
tem: in the first passage of Vero cells 2.1 HAU were
obtained at 96 hpi, whereas in the fifth passage a titer of
2.7 HAU at 72 hpi was reached (data not shown). The
HA N-glycosylation pattern of the MDCK cell-derived
IVA-Uruguay seed exhibited 25 different characteristic
peaks in the range of 160 bp to 400 bp. Of these a total
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any medium, provided the original work is properly cited.Figure 1 HA N-glycosylation patterns of Influenza A virus Uruguay/716/2007 (H3N2) – high growth reassortant. Relative fluorescence
units (RFU) are plotted over the migration time (tmig) in base pairs (bp). (A) MDCK cell-derived virus (seed) was consecutively passaged in Vero
cells (1
st passage to 5
th passage). Peaks annotated in blue are present in MDCK as well as Vero cell-derived HA; peaks annotated in black are
MDCK cell-specific, and red annotation indicates Vero cell-specific peaks. (B) MDCK cell-derived virus harvested either 24 or 72 hours post
infection (hpi). MDCK cell-specific peaks are annotated (1, 2, 4, 6 – 24, 26-28).
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400 bp; #12, 13, 18 - 22, 24, 26 - 28) were unique to
MDCK cell-derived virus (figure 1A). In contrast, the
HA N-glycosylation pattern changed significantly with
the first passage in Vero cells. Here, 15 different peaks
between 150 bp and 380 bp characterize the Vero cell-
specific HA N-glycosylation pattern. Four peaks (#3, 5,
23 and 25) were unique to Vero cell-derived virus (fig-
ure 1A). In comparison to MDCK cell-derived HA, the
Vero cell-derived antigen showed a tendency towards
smaller glycan structures. The relative abundance of
each peak over all Vero passages only varied marginally
with standard deviations (SD) ≤ 2.1 % (table 1). The
increase in virus titers within shorter time frames sug-
gests increased viral fitness, during adaptation from
MDCK to Vero cells. An impact of HA N-glycosylation
on properties of the virus, i.e. virus replication, has
already been descried [8-12]. Interestingly, the glycan
pattern stabilized soon after the first passage in Vero
cells. This clearly indicates that further increase in HA
titer did not depend on changes in the HA N-glycosyla-
tion pattern.
The impact of harvest time on the HA N-glycosylation
pattern of MDCK cell-derived IVA-Uruguay is shown in
figure 1B. Virus harvested at either 24 hpi or 72 hpi
exhibited the 25 different MDCK cell-specific peaks
between 160 bp and 400 bp. At 72 hpi one additional,
but very low abundant peak was detected (numbered
23). Overall, differences in relative structure abundance
were rather small with a maximal difference of 1.7 %
Table 1 Overview of relative peak heights (RPH) of 28 HA-glycan peaks during virus adaptation from MDCK to Vero cells, and
of two harvest time points in a cultivation with MDCK cells. For virus adaptation, MDCK cell-derived virus seed was
consecutively passaged in Vero cells (pass. 1 to pass. 5). Two harvest time points, 24 and 72 hours post infection
(hpi), compared by absolute values of RPH and percentage difference |ΔRPH|. Maximal SD and maximal |ΔRPH| are
highlighted in bold.
Peak Virus Adaptation Time Course
seed pass. 1 pass. 2 pass. 3 pass. 4 pass. 5 pass. 1 to 5 24 hpi 72 hpi |ΔRPH|
No. Relative Peak Height (RPH) [%] SDRPH* [%] RPH [%] [%]
1 7,8 0,9 1,7 0,9 2,2 4,8 1,6 3,9 4,5 0,6
2 3,9 5,7 4,6 5,1 6,1 4,3 0,7 2,4 2,8 0,4
3 0,0 2,2 1,9 3,4 1,4 1,4 0,8 0 0 0
4 8,1 6,6 5,9 6,1 6,8 6,8 0,4 5,3 5,2 0,1
5 0,0 4,0 2,7 2,5 2,5 1,9 0,8 0 0 0
6 1,4 2,5 1,9 1,5 1,5 1,7 0,4 2,1 1,7 0,4
7 6,2 4,4 4,8 4,1 4,7 4,8 0,3 4,0 3,6 0,4
8 6,5 10,0 9,6 8,1 7,4 7,6 1,2 5,3 5,2 0,1
9 1,7 4,3 3,4 3,4 4,1 5,6 0,9 1,1 1,1 0
10 13,7 25,8 23,5 27,2 28,6 24,3 2,1 17,6 16,3 1,3
11 6,8 11,8 12,3 12,2 11,7 9,5 1,2 5,5 4,9 0,6
12 6,2 0 0 0 0 0 0 2,5 2,5 0
13 2,0 0 0 0 0 0 0 4,6 4,4 0,2
14 3,1 0,6 1,1 1,9 1,3 1,5 0,5 3,7 3,6 0,1
15 6,3 4,1 4,1 4,4 3,8 3,5 0,3 5,0 4,7 0,3
16 2,2 7,7 7,4 7,4 7,8 8,9 0,6 5,9 6,0 0,1
17 1,6 3,3 4,4 3,3 3,1 4,3 0,6 2,3 2,8 0,5
18 1,3 0 0 0 0 0 0 1,9 2,3 0,4
19 4,5 0 0 0 0 0 0 3,6 4,1 0,5
20 2,0 0 0 0 0 0 0 8,0 7,0 1,0
21 2,6 0 0 0 0 0 0 1,7 2,2 0,5
22 3,3 0 0 0 0 0 0 3,9 3,8 0,1
23 0,0 4,7 7,9 6,2 5,0 6,4 1,3 0 1,7 1,7
24 1,9 0 0 0 0 0 0 1,6 1,7 0,1
25 0,0 1,5 3,0 2,3 1,9 2,6 0,6 0 0 0
26 2,4 0 0 0 0 0 0 2,2 2,1 0,1
27 1,1 0 0 0 0 0 0 2,3 2,3 0
28 3,1 0 0 0 0 0 0 3,7 3,4 0,3
* standard deviation (SDRPH) of all characteristic peaks in MDCK and Vero cells during virus adaptation
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released in the supernatant is rather stable over the time
window relevant for influenza virus production [5,6]].
However, there are minor variations in RPH from pas-
sage to passage during adaptation and between harvest-
ing time points. Possible explanations are varying ratios
either of completely/incompletely processed or of intact/
degraded N-glycan structures or a combination of both.
In 2009, Schwarzer et al. [7] characterized the MDCK
cell-derived HA N-glycosylation pattern of a H3N2
influenza virus subtype as a mixture of complex N-gly-
can structures with terminal a-a n db-galactose and
high mannose type structures. In contrast, the Vero cell-
derived HA was characterized by complex N-glycans
with exclusively terminal b-galactose and structures of
the high mannose type. For final evaluation of the
results presented here, determination of the N-glycan
structure of all peaks would be required.
Conclusion
In this study, the impact of adaptation and harvesting
time point on HA N-glycosylation of IVA-Uruguay was
investigated. So far, it is not clear whether differences in
the HA N-glycosylation have an impact on immuno-
genicity or other properties of influenza vaccines. Other
factors, e.g. differences in cell culture media, cell density,
etc. may also contribute to variations in HA N-glycosy-
lation. Nevertheless, monitoring N-glycosylation patterns
during vaccine production processes allows not only to
evaluate antigen quality and the impact of process modi-
fications on lot-to-lot consistency but also to critically
assess consequences of unwanted process variations or
process failure.
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